Description
Release form
Tablets.
Packing
20 pcs.
Pharmacological action
Novocainamide has a membrane-stabilizing effect.
Reduces the excitability and conduction of the heart muscle, inhibits the formation of impulses in the foci of automatism, has a local anesthetic effect.
Indications
Used for various cardiac arrhythmias:
Ventricular arrhythmias.
Extrasystole.
Paroxysmal ventricular tachycardia.
Supraventricular arrhythmias.
Paroxysmal atrial fibrillation or atrial flutter.
Contraindications
Hypersensitivity to the drug.
Atrioventricular block 2 and 3 degrees.
Myocardial infarction.
Blockade of the legs of the bundle of His.
Arrhythmias associated with cardiac glycoside intoxication.
Severe heart failure.
Severe renal failure.
Arterial hypotension.
Cardiogenic shock.
Severe atherosclerosis.
Systemic diseases of the connective tissue.
Bronchial asthma.
myasthenia gravis.
Use during pregnancy and lactation
With the use of procainamide during pregnancy, there is a potential risk of accumulation of the substance and the development of arterial hypotension in the mother, which can lead to uteroplacental insufficiency.
Special instructions
Take on an empty stomach (1 hour before meals or 2 hours after meals) with a glass of water for faster absorption or with food or milk to prevent irritation of the gastric mucosa for prolonged-release tablets – swallow whole, Do not crush, crush, or chew.
Before iv use, it must be diluted, administered at a rate of no higher than 50 mg / min should be taken only in a hospital setting.
During therapy, it is necessary to monitor blood pressure, ECG, peripheral blood formulas, especially the number of leukocytes (every 2 weeks during the first 3 months of therapy, then at longer intervals).
After prolonged maintenance therapy, approximately 80% of patients have an increase in the titer of antinuclear antibodies, most often 1-12 months after the start of therapy (in connection with the appearance of symptoms similar to SLE, it is necessary to periodically determine the titer of antinuclear antibodies).
Leukopenia is more likely when prolonged-release dosage forms are used, especially after surgery on the heart or blood vessels. It is usually noted in the first 3 months of therapy (the blood formula is restored a few weeks after withdrawal).
When used in children to maintain therapeutic concentrations, higher doses may be required in the elderly, more likely to develop hypotension.
Care must be taken when interpreting laboratory results (possible effect on test results).
When prescribed during pregnancy, there is a potential risk of maternal arterial hypotension, which can lead to uteroplacental insufficiency.
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.
Composition
Novocainamide 0.25 g (250 mg).
Dosage and administration
Take the drug inside, regardless of the meal.
For relief of ventricular extrasystole
0.25-1.0 g, then 0.25-0, 5 g every 3-6 hours (if necessary, the dose can be increased to 3-4 g).
With paroxysms of atrial fibrillation
1.0-1.5 g (once). After 1 hour (in the absence of a therapeutic effect) another 0.5 g and then every 2 hours, 0.5-1.0 g (until relief of paroxysm).
Side effects of
From the nervous system: hallucinations, depression, myasthenia gravis, dizziness, headache, cramps, psychotic reactions with productive symptoms, ataxia.
From the digestive system: bitterness in the mouth.
From the hemopoietic organs and hemostasis: with prolonged use – inhibition of bone marrow hematopoiesis (leukopenia, thrombocytopenia, neutropenia, agranulocytosis, hypoplastic anemia), hemolytic anemia with a positive Coombs test.
From the sensory organs: taste disturbances.
From the CCC side: decreased blood pressure, ventricular paroxysmal tachycardia. With rapid iv administration, collapse, violation of atrial or intraventricular conduction, asystole are possible.
Allergic reactions: skin rash.
Other: with prolonged use – medicinal lupus erythematosus (in 30% of patients with a duration of therapy more than 6 months).
Microbial infections, delayed healing processes, and bleeding gums are likely due to the risk of leukopenia and thrombocytopenia.
Drug interaction
Enhances the effect of antiarrhythmic, antihypertensive, anticholinergic and cytostatic drugs, muscle relaxants, side effects of bretilium tosylate. With simultaneous use with antihistamines, atropine-like effects with a pimozode may intensify – lengthening the QT interval.
Reduces the activity of anti-myasthenic drugs.
Cimetidine decreases renal clearance of procainamide and prolongs T1 / 2.
In combination therapy with antiarrhythmic drugs (including quinidine, amiodarone, lidocaine), the risk of developing an arrhythmogenic effect increases.
Enhances the cardiodepressive effect of lidocaine.
The concentration of procainamide in plasma is increased by cimetidine, ranitidine, beta-blockers, amiodarone, trimethoprim, quinidine, ofloxacin.
Concomitant use with sparfloxacin is not recommended.
drugs that inhibit bone marrow hematopoiesis increase the risk of myelosuppression.
overdose
Symptoms: confusion, decreased urination, severe dizziness or fainting, palpitations or irregular heartbeat, nausea or vomiting.
Treatment: If you have the above symptoms of overdose, you need urgent medical advice. Before the arrival of the doctor it is recommended to drink a large amount of liquid (2-3 l) and cause vomiting.
Storage conditions
Store in a dark place.
Shelf life
3 years.
Deystvuyushtee substance
Procainamide
dosage form
tablets
Possible Product Names
NOVOKINAMID 0.25 N20 TABLE
Novocainamide 0.25g Tab. X20 B (R)
NOVOKINAMID 250MG. No. 20 TAB.
Novokainamid tab. 0.25g No. 20
Novokainamid tab. 250mg x 20
Organics, Russia
